Patent ID: 8187800
Filing Date: 2012-05-29
Classification: G01N

Abstract:
1. A method of selecting docetaxel and 5-fluorouracil (DF) as a neoadjuvant chemotherapy predictive of pathological complete response for a breast cancer patient, comprising: preparing one or more explants for cell culture from a transcutaneous biopsy specimen from the patient; growing one or more cell monolayers from said explants, the monolayers comprising malignant cells; exposing cells from said monolayers to docetaxel and 5-fluorouracil (DF), and at a range of concentrations; measuring a response of the cells to docetaxel and 5-fluorouracil (DF) within said range; preparing a dose-response curve for docetaxel and 5-fluorouracil (DF); scoring the sensitivity of the cells to docetaxel and 5-fluorouracil (DF) by calculating an area under said dose-response curve (AUC); and selecting docetaxel and 5-fluorouracil (DF) as the neoadiuvant chemotherapy when the cells exhibit sensitivity to docetaxel and 5-fluorouracil (DF).